Browse the evidence

Insulin regulates adipose tissue development and function by activating specific insulin receptor (INSR) splice variants (INSR-A and INSR-B) and downstream signaling cascades (PI3K/AKT), which control glucose uptake, lipid storage, and adipokine secretion.

Understand that insulin is essential for healthy fat tissue function, including cell survival and the release of beneficial hormones. The goal is not to eliminate insulin, but to maintain sensitivity so it can perform these critical roles without causing metabolic dysfunction.

Visceral adipose tissue (VAT) exhibits higher rates of insulin-stimulated glucose uptake and more rapid insulin signaling activation compared to subcutaneous adipose tissue (SAT), which may contribute to its distinct metabolic impact.

Not all fat is the same. Visceral fat (around organs) is more metabolically active and responsive to insulin than subcutaneous fat (under the skin), which may explain why visceral fat accumulation is more strongly linked to metabolic risks.

Insulin negatively regulates the secretion of resistin and omentin, while positively regulating the secretion of adiponectin, leptin, and other adipokines, thereby influencing systemic insulin sensitivity and energy balance.

Insulin influences the hormones your fat cells release. It boosts beneficial hormones like adiponectin (which improves insulin sensitivity) and leptin (which regulates appetite), while suppressing others like resistin. This complex interplay helps maintain metabolic balance.

Antidiabetic drugs like metformin and liraglutide exert part of their beneficial effects by modifying gut microbiota composition, specifically by increasing the abundance of Akkermansia muciniphila.

If you are taking metformin or liraglutide, part of their benefit may come from how they change your gut bacteria. This highlights the importance of gut health in diabetes management, even when using medication.

Pharmacological re-activation of AMPK in the liver suppresses hepatic steatosis by inhibiting lipid synthesis and stimulating fatty acid oxidation, whereas genetic loss of AMPK does not cause fatty liver development.

While low AMPK activity is linked to fatty liver, simply having low activity doesn't cause the fat accumulation. However, drugs that activate AMPK (like metformin or specific activators) can help reduce liver fat by blocking fat creation and increasing fat burning. This suggests that targeting AMPK is a valid treatment strategy for fatty liver, even if low AMPK itself isn't the initial cause.

IGF-1 and insulin signaling are critical for suppressing FoxO-mediated protein degradation, and their reduction contributes to muscle atrophy by releasing FoxO inhibition.

Maintaining healthy insulin and IGF-1 levels is crucial for preventing muscle loss. These hormones not only stimulate muscle growth but also actively suppress muscle breakdown pathways. A balanced diet that supports healthy insulin sensitivity is essential for muscle preservation.

Bariatric surgery (RYGB and SG) induces sustained weight loss and metabolic improvements through hormonal and neural mechanisms (increased GLP-1/PYY, decreased ghrelin, altered bile acids) rather than solely through caloric restriction or malabsorption.

For patients with severe obesity, bariatric surgery (RYGB or SG) is the most effective treatment for sustained weight loss and metabolic health. The success is largely due to hormonal changes (increased GLP-1/PYY, decreased ghrelin) that reduce hunger and improve glucose control, rather than just eating less. This suggests that non-surgical treatments targeting these same hormones (like GLP-1 agonists) may be effective alternatives for some.

Inhibition of the Insulin/IGF-1 Signaling (IIS) pathway extends lifespan in multiple species by enhancing mitochondrial function, biogenesis, and mitophagy.

Genetic variants that naturally result in lower IGF-1 levels are associated with human longevity. While not a direct prescription, this suggests that the hormonal environment of reduced growth signaling may be protective against aging, distinct from the muscle-building goals of high IGF-1 in youth.

Metformin is not recommended for treating NAFLD or NASH in humans despite improving insulin sensitivity in animal models.

Do not rely on metformin to treat your fatty liver. While it helps control blood sugar in diabetes, studies show it does not improve liver health in people with NAFLD or NASH. Focus on weight loss and dietary changes instead.

Plasma LEAP2 levels increase with higher body mass, obesity, and postprandial states in humans and mice, acting as an endogenous antagonist to acyl-ghrelin to limit food intake and blood glucose elevation.

Your body produces a hormone called LEAP2 that increases when you are overweight or after you eat. This hormone acts as a brake on the 'hunger hormone' (ghrelin) to prevent you from overeating and spiking blood sugar. This is a natural regulatory mechanism. While high LEAP2 is associated with obesity, it also decreases when you lose weight, suggesting your body's hormonal 'brakes' can adjust as your metabolic state changes.

Increased appetite during a depressive episode is the primary driver of associations between depression and metabolic/inflammatory markers (BMI, metabolic syndrome components, waist circumference, CRP, TNF-α).

If you are depressed and experiencing increased appetite, this is a specific biological subtype ('immuno-metabolic depression') linked to higher inflammation and metabolic risk. It is not just 'overeating' but a symptom. Standard antidepressants may not address this. Discuss with your doctor whether treatments targeting inflammation (like anti-inflammatories or statins, though evidence is mixed) or lifestyle interventions (diet, weight loss) might be beneficial for this specific subtype.

Glucagon receptor signaling regulates hepatic lipid metabolism by stimulating beta-oxidation and inhibiting lipogenesis, thereby reducing hepatic lipid accumulation.

Glucagon plays a crucial role in how your liver handles fat. While high glucagon in diabetes can be problematic, activating glucagon receptors (especially when combined with GLP-1) helps the liver burn fat and reduces liver fat storage. This is why combination therapies are effective for metabolic health.

Glucagon stimulates lipolysis in rodent adipocytes but has no significant lipolytic effect on human adipocytes at physiological concentrations.

Unlike in mice, glucagon does not directly trigger significant fat breakdown in human fat cells at normal levels. Its main job in lipid metabolism is managing fat in the liver, not burning fat from storage cells.

Klotho protein functions as an anti-aging agent by inhibiting four major aging pathways (TGF-β, IGF-1, Wnt, NF-κB) and promoting antioxidant defenses, with deficiency leading to accelerated aging phenotypes and overexpression extending lifespan.

Maintaining healthy kidney function and managing metabolic health (blood sugar, blood pressure) may help preserve natural Klotho levels, which are linked to longevity. While direct Klotho supplementation is not yet a standard consumer intervention, lifestyle factors that support kidney health and reduce inflammation (like exercise and certain diets) are associated with higher Klotho expression.

Aging causes a progressive decline in brown adipose tissue (BAT) mass and thermogenic activity, primarily through mitochondrial dysfunction, reduced sympathetic nervous system stimulation, and hormonal shifts, leading to age-related metabolic alterations.

As you age, your body's ability to burn fat for heat (via brown fat) naturally declines due to changes in hormones, nerve signals, and cell health. This contributes to weight gain and metabolic issues. While you can't stop aging, understanding this process highlights the importance of maintaining metabolic health through lifestyle factors that may support remaining brown fat function, such as staying active and managing stress/hormonal health.

Beige adipose tissue formation declines with age due to defective progenitor cell proliferation and differentiation, potentially linked to changes in the adipose tissue microenvironment and reduced SIRT1 levels.

Your body's ability to create 'beige fat' (fat that burns energy) decreases as you age, partly because the stem cells that make it become less active. This is linked to changes in your body's internal environment and signaling molecules. While this decline is natural, it underscores the importance of maintaining overall metabolic health to support any remaining thermogenic capacity.

Obesity-induced adipose tissue dysfunction and systemic insulin resistance drive the development of MAFLD/NASH, which in turn exacerbates cardiovascular disease risk through the release of pro-atherogenic, pro-coagulant, and pro-inflammatory mediators from the liver.

If you have fatty liver disease (MAFLD/NASH), your liver is actively sending chemical signals that increase your risk of heart disease and stroke, independent of your weight. Managing liver health through weight loss and metabolic control is critical for cardiovascular protection, not just liver protection.

Obesity causes structural and functional cardiac alterations, including left ventricular hypertrophy, diastolic dysfunction, and atrial fibrillation, primarily through increased blood volume, cardiac output, and neuro-hormonal activation (RAAS).

Excess body weight forces your heart to work harder by increasing blood volume and output, leading to thickening of the heart muscle (LVH) and stiffening of the heart chambers. This structural change happens even if you feel no symptoms and increases the risk of heart failure and arrhythmias like atrial fibrillation.

High-fat diet-induced obesity reduces intestinal IgA+ immune cells and secretory IgA, which exacerbates insulin resistance by increasing intestinal permeability, microbial encroachment, and systemic inflammation.

Maintaining gut immune health, specifically IgA levels, may be crucial for managing insulin resistance during high-fat diets. While this study is in mice, it suggests that interventions supporting gut immunity (like certain diets or therapies) might help metabolic health.

Current glucose-lowering therapies, specifically metformin and bariatric surgery, alter intestinal IgA+ B cell populations and fecal secretory IgA levels, respectively.

If you are taking metformin or had bariatric surgery, part of their benefit may come from restoring gut IgA levels, which helps control inflammation and glucose.

The hypothalamus regulates basal metabolic rate (RMR) and adaptive thermogenesis through distinct neuronal populations and hormonal axes, with lean mass and thyroid hormone signaling being primary determinants of energy expenditure.

Focus on preserving lean muscle mass, as it is the largest driver of your resting metabolic rate. Your brain's hypothalamus regulates your baseline calorie burn through hormonal signals (like thyroid and leptin) and neural pathways. While exercise matters, your body's internal 'thermostat' sets the stage for how efficiently you burn energy at rest.

Elevated intracellular ceramide levels induce cellular senescence and contribute to age-related pathologies such as insulin resistance and atherosclerosis, whereas sphingosine-1-phosphate (S1P) delays senescence and promotes cell survival.

This research highlights that cellular aging is driven by specific lipid signals: high ceramide promotes aging/senescence, while S1P promotes youth/survival. While this paper does not prescribe a specific diet, it implies that interventions which lower ceramide or boost S1P (potentially through specific dietary fats or metabolic health) could theoretically delay aging. Focus on metabolic health to maintain favorable sphingolipid balances.

Ceramide accumulation in specific tissues (adipose, liver, muscle) during aging and high-fat diet consumption drives insulin resistance and inflammation, linking sphingolipid metabolism to type 2 diabetes.

High levels of specific lipids called ceramides, particularly C16-ceramide, are linked to insulin resistance and type 2 diabetes. This suggests that managing lipid metabolism and reducing the production of these specific lipids (potentially through diet and exercise) may help prevent or manage insulin resistance.

Females are protected from inflammation-induced muscle wasting (cancer cachexia) compared to males, likely due to estrogen's ability to blunt inflammatory responses and lower basal ubiquitin-proteasome activity.

For women undergoing cancer treatment involving cachexia, hormonal status (specifically estrogen) may offer some natural protection against severe muscle wasting compared to men. This doesn't mean muscle loss won't happen, but the mechanism is different. Maintaining hormonal balance and managing inflammation are key, as estrogen helps blunt the inflammatory signals that drive this specific type of muscle loss.